SEI Investments’s Inovio Pharmaceuticals INO Stock Holding History

SEI Investments’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-56,806	Closed	-$92.6K	–	2849
2025 Q1	$92.6K	Buy	+56,806	New	+$114K	﹤0.01%	2610
2023 Q2	–	Sell	-903	Closed	-$8.89K	–	2718
2023 Q1	$8.89K	Buy	+903	New	+$15.4K	﹤0.01%	2671
2018 Q3	–	Sell	-13	Closed	-$1K	–	2946
2018 Q2	$1K	Buy	+13	New	+$717	﹤0.01%	3472

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SEI Investments's INO Position: Q2 2025 in Review

SEI Investments sold out of Inovio Pharmaceuticals (INO) in Q2 2025, closing a stake of 56,806 shares — an estimated $92.6K sold.

SEI Investments first reported a position in INO in Q2 2018 and held it in 3 quarters. The position peaked at $92.6K in Q1 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2025.

SEI Investments reported no remaining Inovio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SEI Investments sold 56,806 Inovio Pharmaceuticals shares in Q2 2025, an estimated $92.6K.
SEI Investments first reported a position in Inovio Pharmaceuticals in Q2 2018 and held it in 3 quarters.
SEI Investments's Inovio Pharmaceuticals position peaked at $92.6K in Q1 2025.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2025.

Based on SEI Investments's 13F filing for Q2 2025, filed 14 Aug 2025.